

GALDERMA

EST. 1981

2025 MODERN SLAVERY STATEMENT GALDERMA AUSTRALIA PTY LTD

Contents

Introduction	2
Our company	2
Our manufacturing footprint	2
Supply chain and manufacturing: Australia-specific.....	2
Policies and procedures	2
Code of Ethics	2
Supplier Code.....	2
Anti-Bribery and Corruption (ABAC) and Healthcare Compliance Policies	3
Responsible Sourcing SOP	3
Third parties and due diligence	3
Risks of modern slavery practices.....	4
Managing risks	4
Measuring effectiveness.....	5
Training	5
Integrity reporting	5
Consultation.....	6

Note: This document contains forward-looking statements which involve certain risks and uncertainties that could cause actual results to differ materially from those contained in such forward-looking statements.

Introduction

This statement is published in accordance with the Australian Modern Slavery Act 2018 (Cth). It provides an update on the progress that Galderma Australia Pty Ltd (ABN 12 003 976 930) (**Galderma Australia**) has made during the financial year ending 31 December 2025 to prevent modern slavery in its business and supply chain.

Our company

With a unique legacy in dermatology as well as decades of cutting-edge innovation, Galderma is the pure-play dermatology category leader dedicated to advancing dermatology for every skin story. We are strategically positioned in attractive, consumer-driven segments of the dermatology market, characterized by high growth fundamentals. Through trusted partnerships with healthcare professionals, we meet individual consumer and patient needs with superior outcomes.

Galderma is listed as a public company on the SIX Swiss Exchange and is currently active or present in more than 90 countries. In 2025, Galderma generated 5.207 billion USD in net sales. A copy of Galderma's 2025 Annual Report can be found [here](#).

Our manufacturing footprint

Most of Galderma's products continue to be manufactured at production facilities located in Alby-sur-Chéran, France; Baie d'Urfé, Canada; Hortolândia, Brazil, and Uppsala, Sweden. Galderma's remaining products are manufactured by contract manufacturers.

Supply chain and manufacturing: Australia-specific | In the case of Galderma's operations in Australia, we do not have any local manufacturing operations. All of Galderma Australia's finished goods are sourced from our global factories or directly from contract manufacturers who service Galderma globally. To meet any additional needs in Australia, we engage a multitude of vendors for services including transport, warehousing, re-packing, marketing and employment services.

Galderma Australia has a branch office in New Zealand which was registered on 8 January 2024. Despite having such branch office in New Zealand, Galderma distributes its products and services through a third party partner in New Zealand.

Policies and procedures

Galderma strives for the highest standards of integrity, with well-defined governance and a framework of standard operating procedures and policies which guide how our company, employees and partners conduct their business. Core to our compliance framework are the following Codes and Policies:

Code of Ethics | Our [Code of Ethics](#) is an express declaration of adherence to the highest ethical standards in our work. It sets out Galderma's values and principles for business conduct and states that it is the responsibility of every Galderma employee to "*do the right thing, the right way*" to ensure the highest standards of integrity. It means that when we create value for our company and its stakeholders, such as the people and communities we serve, we should do so by acting in an ethical and socially responsible way. Galderma expressly commits to embracing diversity and respecting the personal dignity, privacy and personal rights of every employee and is committed to maintaining a workplace free from discrimination and harassment.

Supplier Code | Our [Supplier Code](#) sets out the standards we expect our suppliers to adhere to when conducting business for us. These standards concern the environment, social aspects and business ethics and form an integral part of our contractual arrangements with our suppliers. It is the supplier's responsibility to communicate our standards to their employees,

agents and subcontractors and to train them accordingly. Our Supplier Code covers the following:

- **Prison and forced labor:** The supplier must under no circumstances use or in any other way benefit from forced labor. Likewise, labor in the form of indentured servitude is prohibited, as is the use of corporal punishment, confinement, threats of violence or other forms of harassment or abuse as a method of discipline or control.
The supplier shall not utilize factories or production facilities that oblige work to be carried out by unpaid or indentured laborers, nor shall the supplier contract for the manufacture of products with subcontractors that engage in such practices or utilize such facilities.
- **Child labor:** As referenced by the International Convention for Children's Rights (art.32) and the Organisation internationale du Travail (OIT) convention (art. 138 and 182), the use of child labor by the supplier is strictly prohibited as it places children at risk or can compromise their schooling or negatively impact their physical, mental, spiritual, moral or social development.
- **Working hours:** The supplier must ensure that their employees work in compliance with all applicable laws and mandatory industry standards pertaining to the number of hours and days worked. In the event of conflict between a statute and a mandatory industry standard, the supplier must comply with such requirement taking precedence under national law.
- **Compensation:** The supplier's employees must be provided with wages and benefits that comply with national and local applicable laws and binding collective agreements, including those pertaining to overtime work and other premium pay arrangements and social protection related terms.
- **Workplace environment:** The supplier shall provide employees with safe and healthy working/housing conditions. At the very least, potable drinking water, adequate sanitation, fire exits and essential safety equipment, access to emergency medical care, appropriately lit and equipped workstations must be provided. In addition, facilities must be constructed and maintained in accordance with standards set by applicable codes and ordinances.

Anti-Bribery and Corruption (ABAC) and Healthcare Compliance Policies | Galderma's Anti-Bribery and Anti-Corruption Policy builds on the core principles of the Code of Ethics, is consistent with international standards and laws and provides the minimum ABAC requirements for Galderma and its partners. Galderma prohibits all forms of bribery and corruption, whether involving a government official or private person or entity and whether direct or through a third party. Galderma's company-wide ABAC program is further strengthened and complemented by a key set of Healthcare Compliance Policies that, cover, among other things, the following areas of activity:

- the provision of Gifts and Educational Items to Healthcare Professionals;
- the engagement of Healthcare Professionals for consulting services;
- the provision of hospitality (meals, travel and accommodation) to Healthcare Professionals; and
- the supply of free of charge samples to Healthcare Professionals.

Responsible Sourcing SOP | Our Responsible Sourcing SOP aims to ensure that all materials and services procured are sourced in a manner that is ethical, sustainable, and compliant with all relevant regulations. This includes ensuring that all suppliers adhere to high standards of ethical conduct, including fair labor practices such as providing minimum living wages and respect for human rights such as prohibiting forced or child labor. This procedure applies worldwide to all Galderma and subsidiary or affiliated company staff members, consultants, contract workers and temporary staff.

Third parties and due diligence

At Galderma, we understand that there is a potential exposure to Modern Slavery when we are purchasing goods and services from third parties. Any third party engaged by Galderma

must conduct business ethically and is expected to comply with all our standards, including those laws and regulations relevant to where we operate (or where our third party partners operate on our behalf).

Galderma applies a risk-based approach when conducting due diligence on its third parties. This includes vetting of any third party prior to such third party's engagement, continuous monitoring throughout the duration of the relationship and ensuring appropriate training is provided to and by all such third parties. Galderma has in place a comprehensive and robust distributor governance model which includes an enhanced risk-based due diligence process. Additionally, Galderma continued to further enhance its Third Party Due Diligence Program and, in 2025, implemented third party due diligence technology to support broader diligence across its operations.

Galderma also audits its key suppliers' Corporate Social Responsibility (CSR) commitments using *Ecovadis* and takes this into account during its sourcing processes. *Ecovadis* assesses companies based on their performance in terms of environment, labor & human rights, ethics and sustainable procurement.

Risks of modern slavery practices

Approximately 70% of Galderma Australia's units sold are produced by our global factories but production of certain products and formulations is outsourced. Given our deployment of contract manufacturers, several social and labor risks may arise in the supply chain:

- Labor Rights Violations in Manufacturing Facilities: Although we do not have any local manufacturing operations in Australia, there is a risk that contract manufacturers based elsewhere may engage in labor rights violations, such as poor working conditions, low wages, excessive working hours, or forced labor. Lack of oversight of these facilities make it more challenging to ensure compliance with labor standards.
- Supply Chain Transparency: Limited visibility into the practices of contract manufacturers can make it difficult to assess and address labor risks effectively. Without transparency, it is harder to identify and remediate issues related to modern slavery, human trafficking, or other forms of exploitation.
- Subcontractor Practices: Contract manufacturers may subcontract certain production processes to other facilities or suppliers, introducing additional layers of complexity and potential new risks. Subcontractors may not adhere to the same labor standards or ethical principles as the primary manufacturers.
- Transportation and Logistics: The engagement of multiple vendors for transport, warehousing, and re-packing services increases the risk of labor abuses within these operations. Drivers, warehouse workers, and other personnel involved in the logistics chain may face exploitation, unsafe working conditions, or wage theft.

Managing risks

Galderma has established fit-for-purpose enterprise risk management (ERM) processes in its Group Risk Policy to support the achievement of its strategic goals and corporate governance responsibilities.

The purpose of the Group Risk Policy is to reflect Galderma's governance and decision-making framework in roles and responsibilities for effective risk management to identify, communicate, and manage material risks facing the organisation in achieving its objectives.

Risk management at Galderma is not a cyclical process with a start and an end, but rather a concept that is embedded in the governance of high-quality decision-making processes through which risks are managed at all levels of the organisation and throughout all stages of doing business: planning, prioritization, execution and evaluation.

Galderma's Risk Policy articulates how the quality of decision-making processes give management the confidence to take risks and pursue opportunities.

- This Risk Policy recognizes that taking risk is integral to doing business and risk management is integral to good management practice and effective corporate governance.
- This Risk Policy aims to ensure decisions are made with sufficient awareness of, and information about, risks and opportunities, and about the organisation's ability to manage these risks and opportunities.

Galderma has risk forums at both the global and regional level whose role(s) is to manage and oversee such risks related to the execution of decisions.

A comprehensive ABAC compliance monitoring program was launched in 2024, introducing a company-wide, systematic approach towards periodically evaluating risk, and continuous monitoring and tracking of related mitigating measures and controls. By 2025, the program had been rolled out across 17 affiliates, including the United Kingdom, Australia and New Zealand, strengthening consistency, oversight and risk management across Galderma's operations. This company-wide rollout is expected to be completed in 2026.

Galderma policies and standard operating procedures are regularly reviewed and updated, and additional training plans are developed to address those risks which are considered high.

Galderma has mandated highly reputable rating agencies to perform audits on selected suppliers at regular intervals. As part of such audits, suppliers are required to submit their policies and compliance certificates, the scope being based on, among other things, the risks associated with the country/location, the industry within which a supplier operates and Galderma's own financial commitment to such supplier.

Measuring effectiveness

As part of Galderma's continuing development of its Risk Management and Compliance programs, Galderma has in place, and looks to continuously enhance, appropriate tools to measure the effectiveness of such programs.

These include field and transaction monitoring of activities across Galderma, conducting country risk assessments, assessing reports submitted through Galderma's Integrity Reporting Hotline (and recorded outcomes), assessing matters raised through, and within, global and regional risk and compliance forums, overseeing global and regional training completion rates and auditing supplier compliance with the Supplier Code.

Training

Since 2019¹, Galderma has significantly progressed in the establishment of necessary corporate structures, including a robust compliance and ethics organisation and program with a compliance training framework which ensures regular training on its key Codes and Policies is provided to all employees. Further global and local training has been rolled out throughout 2024 and 2025, including targeted training on Galderma's Code of Ethics, Anti-Bribery and Anti-Corruption Policy and Data Privacy Policy in addition to training given to all new employees on Galderma's Code on Interactions with Healthcare Professionals, Code of Ethics and Anti-Bribery and Anti-Corruption Policy.

Integrity reporting

Galderma's Integrity Reporting Platform provides employees as well as third parties with a channel to speak up and report incidents or violations (or suspected violations) of law or violations (or suspected violations) of Galderma's Code of Ethics or policies, or to share concerns if they believe that someone has done, or may be about to do, something which constitutes unprofessional or unethical behavior. Reports to Galderma's Integrity Reporting Platform can be made anonymously and are treated confidentially to the extent permitted by local law.

¹ When Galderma became an independent company following acquisition by a consortium of institutional investors in October 2019

In 2025, Galderma implemented a new Integrity Reporting system, replacing its previous provider, to further enhance accessibility and oversight of speak-up reporting across the organisation. Galderma recognises that the continued success of its business depends on the open communication of concerns, including those related to Modern Slavery, by directors, officers, employees and third parties without fear of retaliation.

Consultation

This statement was prepared in consultation with relevant global and regional subject matter experts within Galderma including procurement, supply chain, human resources, legal & compliance, ESG & sustainability and finance, with additional specific input from key personnel in Galderma Australia Pty Ltd.

The senior leadership team of Galderma Australia Pty Ltd was given an opportunity to consider and provide comments on this statement prior to publication. This statement was approved by the Galderma Australia Board of Directors on 26 June 2026.

Galderma Australia Pty Ltd

A handwritten signature in black ink, appearing to read 'Rosemary Jolic', written over a faint, illegible stamp.

Rosemary Jolic

General Manager Australia
and New Zealand

Date: 26 June 2026